Role of the UGT2B17 deletion in exemestane pharmacogenetics

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases

(2016) Amity Platt et al.   Pharmacogenetics and Genomics

Impact ofUGT2B17Gene Deletion on the Pharmacokinetics of 17-Hydroexemestane in Healthy Volunteers

(2015) Shanly M. Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Validation of a Rapid and Sensitive LC-MS/MS Method for Determination of Exemestane and Its Metabolites, 17β-Hydroxyexemestane and 17β-Hydroxyexemestane-17-O-β-D-Glucuronide: Application to Human Pharmacokinetics Study

(2015) Ling-Zhi Wang et al.   PLoS One

Mechanisms of Endocrine Resistance in Breast Cancer

(2010) C. Kent Osborne et al.   Annual Review of Medicine

Glucuronidation Genotypes and Nicotine Metabolic Phenotypes: Importance of Functional UGT2B10 and UGT2B17 Polymorphisms

(2010) G. Chen et al.   CANCER RESEARCH

In Vitro Cytochrome P450-Mediated Metabolism of Exemestane

(2010) L. K. Kamdem et al.   DRUG METABOLISM AND DISPOSITION

Determination of exemestane and 17-hydroxyexemestane by high-performance liquid chromatography coupled with tandem mass spectrometry and high-resolution mass spectrometry

(2010) E. N. Semenistaya et al.   JOURNAL OF ANALYTICAL CHEMISTRY

Characterization of 17-dihydroexemestane glucuronidation: potential role of the UGT2B17 deletion in exemestane pharmacogenetics

(2010) Dongxiao Sun et al.   Pharmacogenetics and Genomics

A Comparative Study of Exemestane Versus Anastrozole in Patients with Postmenopausal Breast Cancer with Visceral Metastases

(2009) Susana M. Campos et al.   Clinical Breast Cancer

Exemestane

(2009) Emma D. Deeks et al.   DRUGS

History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target

(2009) R. J. Santen et al.   ENDOCRINE REVIEWS

A liquid chromatography‐tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17‐dihydroexemestane in human plasma

(2009) Giuseppe Corona et al.   JOURNAL OF MASS SPECTROMETRY

Mechanism-based categorization of aromatase inhibitors: a potential discovery and screening tool

(2009) P.I. Petkov et al.   SAR AND QSAR IN ENVIRONMENTAL RESEARCH

Genome-wide Copy-Number-Variation Study Identified a Susceptibility Gene, UGT2B17, for Osteoporosis

(2008) Tie-Lin Yang et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review

(2008) Andrea Eisen et al.   CANCER TREATMENT REVIEWS

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY